老年社区获得性肺炎(痰浊阻肺证)患者应用苏子降气汤合三子养亲汤联合盐酸氨溴索治疗的效果及安全性分析
DOI:
CSTR:
作者:
作者单位:

黄河科技学院附属医院呼吸内科 河南 郑州 450000

作者简介:

通讯作者:

中图分类号:

基金项目:


Analysis of the efficacy and safety of Suzi Jiangqi decoction and Sanzi Yangqin decoction combined with ambroxol hydrochloride in the treatment of elderly patients with community-acquired pneumonia (phlegm turbidity obstructing lung syndrome)
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 探讨老年痰浊阻肺型社区获得性肺炎(CAP)患者应用苏子降气汤合三子养亲汤联合盐酸氨溴索的治疗效果。方法 前瞻性选取我院收治的148例老年痰浊阻肺型CAP患者(选例时间:2023年1月-2025年11月)为研究对象,随机分为参照组(74例,采用盐酸氨溴索治疗)、中药组(74例,加用苏子降气汤合三子养亲汤治疗)。比较两组不良反应发生率、临床疗效及治疗前、后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气流量峰值(PEF)、FEV1/FVC]、细胞免疫功能指标[CD3+<sup>、</sup>CD4+<sup>/CD8</sup>+<sup>、</sup>CD4+<sup>、</sup>CD8+<sup>]</sup>、中医证候积分、炎症介质[淀粉样蛋白A(SAA)、CXC趋化因子配体10(CXCL10)、白细胞介素-6(IL-6)、正五聚蛋白3(PTX3)]水平。结果 与参照组总有效率(83.78%)相比,中药组(95.95%)明显升高(P<0.05);治疗后中药组SAA、各中医证候积分、CXCL10、CD8+<sup>、</sup>IL-6、PTX3水平较参照组低(P<0.05),FVC、CD3+<sup>、</sup>FEV1、CD4+<sup>/CD8</sup>+<sup>、</sup>PEF、CD4+<sup>、</sup>FEV1/FVC水平较参照组高(P<0.05);不良反应发生情况组间比较无明显差异(P>0.05)。结论 苏子降气汤合三子养亲汤+盐酸氨溴索治疗老年痰浊阻肺型CAP效果显著,可减轻炎症反应、临床症状,改善肺功能与细胞免疫功能。

    Abstract:

    Objective To investigate the therapeutic efficacy of Suzi Jiangqi Decoction and Sanzi Yangqin Decoction combined with ambroxol hydrochloride in elderly patients with community-acquired pneumonia (CAP) of phlegm turbidity obstructing lung syndrome. Methods A total of 148 elderly patients with phlegm-turbidity obstructing lung type CAP admitted to our hospital were prospectively selected as the study subjects (selection time: January 2023-November 2025). They were randomly divided into reference group (74 cases, treated with ambroxol hydrochloride) and Chinese medicine group (74 cases, treated with additional Suzi Jiangqi Decoction and Sanzi Yangqin Decoction combined with ambroxol hydrochloride). The incidence of adverse reactions and clinical efficacy were compared between the two groups, as well as the lung function indexes [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), FEV1/FVC], cellular immune function indexes [CD3+<sup>, CD4</sup>+<sup>/CD8</sup>+<sup>, CD4</sup>+<sup>, CD8</sup>+<sup>], TCM syndrome scores</sup>, inflammatory mediators [amyloid A (SAA), CXC chemokine ligand 10 (CXCL10), interleukin-6 (IL-6), pentraxin 3 (PTX3)] levels before and after treatment. Results Compared with the total effective rate of the reference group (83.78%), the Chinese medicine group (95.95%) was significantly higher (P<0.05); after treatment, the levels of SAA, TCM syndrome scores, CXCL10, CD8<sup>+</sup>, IL-6 and PTX3 in the Chinese medicine group were lower than those in the reference group (P<0.05), and the levels of FVC, CD3+<sup>, FEV</sup>1, CD4+<sup>/CD8</sup>+<sup>, PEF, CD4</sup>+<sup> and FEV</sup>1/FVC were higher than those in the reference group (P<0.05). There was no significant difference being found in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Suzi Jiangqi Decoction combined with Sanzi Yangqin Decoction + Ambroxol Hydrochloride is effective in the treatment of CAP in elderly patients with phlegm turbidity obstructing lung syndrome, which can reduce inflammatory reaction and clinical symptoms, and improve lung function and cellular immune function.

    参考文献
    相似文献
    引证文献
引用本文
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2026-05-25
  • 最后修改日期:2026-08-03
  • 录用日期:2026-09-14
  • 在线发布日期:
  • 出版日期:
文章二维码